We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

167 hedge funds and large institutions have $1.94B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 56 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $8.54M

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

5% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 56

8% less funds holding

Funds holding: 182167 (-15)

21% less capital invested

Capital invested by funds: $2.47B → $1.94B (-$527M)

39% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 38

Holders
167
Holders Change
-15
Holders Change %
-8.24%
% of All Funds
2.93%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.11%
New
23
Increased
59
Reduced
56
Closed
38
Calls
$13.7M
Puts
$8.54M
Net Calls
+$5.2M
Net Calls Change
-$5.03M
Name Holding Trade Value Shares
Change
Change in
Stake
RG
1
Redmile Group
California
$195M -$4.02M -86,324 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$177M +$5.23M +112,304 +3%
Franklin Resources
3
Franklin Resources
California
$172M +$11.8M +253,895 +7%
BlackRock
4
BlackRock
New York
$156M +$3.5M +75,145 +2%
AllianceBernstein
5
AllianceBernstein
Tennessee
$89.4M +$22.7M +487,445 +32%
State Street
6
State Street
Massachusetts
$83.4M +$1.16M +24,962 +1%
ACH
7
ArrowMark Colorado Holdings
Colorado
$72.2M +$2.8M +60,183 +4%
O
8
OrbiMed
New York
$61.9M +$11.9M +255,200 +23%
NLVP
9
New Leaf Venture Partners
New York
$54.2M
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$52.4M -$308K -6,624 -0.6%
CCM
11
Consonance Capital Management
New York
$44.6M +$23.7M +509,241 +105%
ACA
12
Avoro Capital Advisors
New York
$40M -$18.9M -407,000 -31%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$35.9M -$30.2M -647,945 -45%
PAMU
14
Pictet Asset Management (UK)
United Kingdom
$33.2M
Geode Capital Management
15
Geode Capital Management
Massachusetts
$31.6M +$2.38M +51,224 +8%
Alkeon Capital Management
16
Alkeon Capital Management
New York
$30.1M
Goldman Sachs
17
Goldman Sachs
New York
$27.8M +$1.67M +35,940 +6%
Wells Fargo
18
Wells Fargo
California
$24.6M -$7.14M -153,397 -22%
DM
19
Deerfield Management
New York
$23.7M
SHI
20
SV Health Investors
Massachusetts
$20.2M
NIP
21
Nicholas Investment Partners
California
$20M +$8.65M +185,876 +71%
Northern Trust
22
Northern Trust
Illinois
$19.7M -$792K -17,008 -4%
Janus Henderson Group
23
Janus Henderson Group
United Kingdom
$19.1M +$4.25M +91,239 +27%
Invesco
24
Invesco
Georgia
$18.3M +$442K +9,484 +2%
PCH
25
Polar Capital Holdings
United Kingdom
$17.9M +$2.33M +50,000 +14%

DCPH Hedge Fund Activity: Q1 2021 in Review

167 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2021, worth a combined $1.94B — down 21% from $2.47B a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of DCPH and 23 opened new positions — a net loss of 15 holders — while 56 trimmed existing stakes and 59 added.

The largest buyer was Consonance Capital Management, adding an estimated $23.7M. The largest seller was Fidelity Investments, cutting an estimated $30.2M.

  • 167 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2021, down from 182 in Q4 2020.
  • Funds reported $1.94B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2021, down 21% quarter-over-quarter.
  • 23 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 38 closed out, a net change of -15 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Consonance Capital Management, an estimated $23.7M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Fidelity Investments, an estimated $30.2M sold.

Based on aggregated 13F filings for Q1 2021.